transition therapeutics usa inc private company information  bloomberg july    pm et pharmaceuticals company overview of transition therapeutics usa inc snapshot people company overview transition therapeutics usa inc engages in discovering and developing pharmaceutical products it was formerly known as pharmaceutical assets and business unit in california the company was founded in  and is based in san diego california as of august   transition therapeutics usa inc operates as a subsidiary of transition therapeutics inc san diego ca united statesfounded in  key executives for transition therapeutics usa inc dr john nestor vice president of drug discovery compensation as of fiscal year  similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact transition therapeutics usa inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close transition therapeutics  tthi  stock price  news  the motley fool skip to main content the motley fool foolcom foolcouk foolcomau foolca foolsg foolde helping the world invest better since  hi fool premium advice help fool answers contact us login search search transition therapeutics tthi more tthi pages overview interactive chart options historical prices dividends news  headlines profile company events sec filings earningsgrowth financial ratios wall st opinion major holders insider trades insider roster income statement balance sheet cash flow tthi stock quote    bats bzx real time price as of december    pm transition therapeutics inc transition is a productfocused biopharmaceutical company developing therapeutics for disease indications with large markets updates from the motley fool latest updates on transition therapeutics from foolcom opko health sets its sights on diabetes its most recent acquisition is a tiny company with an intriguing midstage type  diabetes therapy jul    •  foolcom  stocks near week highs worth selling are these three stocks sells or belles you be the judge mar    •  foolcom eli lilly to take over development of diabetes drug eli lilly to pay transition therapeutics  million initially for the drug being developed to tre jun    •  foolcom view more headlines » tthi stock quote    bats bzx real time price as of december    pm stock performance view interactive tthi charts sponsored by key data points primary metrics and data points about transition therapeutics current price  prev close  open  bid  ask  days range    wk range    volume  avg vol  market cap  pe ttm  eps ttm  div  yield   ceo rating the single most important factor in a companys success is the team thats leading the company tony f cruz ceo  approve based on  ratings powered by business summary industry sector and description for transition therapeutics transition therapeutics inc transition is a productfocused biopharmaceutical company developing therapeutics for disease indications with large markets exchange nasdaq sector healthcare industry drug makers current tth stock quote  transition therapeutics inc  bloomberg markets error could not add to watchlist x  watchlist transition therapeutics inc tthcn acquired tthcn was acquired by opkus cad volume  before its here its on the bloomberg terminal learn more volume  current pe ratio ttm  earnings per share cad ttm  market cap cad  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases there are currently no news stories for this ticker please check back later there are currently no press releases for this ticker please check back later profile transition therapeutics inc is a biopharmaceutical company focused on developing novel therapeutics in order to address global medical needs in large disease indications including alzheimers disease and diabetes address  college streetsuite toronto on mg lcanada phone  website wwwtransitiontherapeuticscom executives board members tony f cruz chairmanceo carl damiani presidentcoo nicole rusaw george chief financial officer aleksandra pastrak vpclinical devmedical ofcr louis alexopoulos secretary show more bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation about transition corporate overview management team board of directors contact us job opportunities business ethics at transition therapeutics inc the “corporation” we expect our employees officers and directors will comply with our company values the corporation’s values with respect of the code of business conduct and ethics are a respect people and cultural differences b honest and open communications c professional in everything we do d accept individual responsibility as a corporation we value honesty high ethical standards and compliance with laws rules and regulations the following provides guidance on the application of these principles adoption this code of business conduct and ethics was adopted by the board of directors the “board” of the corporation compliance with laws rules and regulations  accounting requirements the corporation and its employees shall follow the accepted rules and controls required by the securities commission in each jurisdiction in which the corporation is a reporting issuer and any stock exchange on which the corporation’s securities are listed further the corporation’s financial statements shall be prepared in accordance with canadian generally accepted accounting principles for additional information on these rules and controls contact the corporation’s chief financial officer  equal employment opportunity and discrimination laws it continues to be the practice of the corporation to employ positive business and personnel practices designed to ensure the full realization of equal employment opportunity further we expect all employees to accomplish their work in a businesslike manner with a concern for the well­being of their co­workers harassment of any employee by any other employee is prohibited regardless of their working relationship any employee who experiences harassment should bring it to the attention of hisher supervisor if the employee is not satisfied that the matter has been appropriately addressed the employee should feel free to contact the chief executive officer of the corporation  securities laws all employees of the corporation are prohibited from transacting in the corporation’s securities for themselves family members friends or any other person while in the possession of material non­public inside information concerning the corporation in addition all employees of the corporation must preclear any trades in the corporation’s securities with the corporation’s chief financial officer or chief executive officer employees must not give inside information to anyone inside information is information that the corporation has not made public about any of its activities such as clinical trial results the issuance of a patent earnings estimates the commencement or outcome of litigation mergers and acquisitions or any other information that could affect the corporation’s fortunes and therefore the price of the stock for more detailed information please refer to the corporation’s “policy on disclosure confidentiality and trading of insiders and employees” available from the corporation’s chief financial officer  health and safety the corporation seeks to provide a clean safe and healthy place to work all employees are expected to observe all safety rules and practices and to follow instructions concerning safe work practices  record keeping and reporting of information all records and reported information must be accurate complete honest and timely  conflicts of interest every employee officer or director is expected to make decisions in the best interest of the corporation and not for personal gain a conflict of interest can arise when an employee officer or director takes action or has a personal interest that may make it difficult to perform his or her work for the corporation objectively and effectively this may include outside business interests outside employment outside investments and business relationships with friends or relatives that could cause a conflict of interest employees officers and directors should report potential conflicts of interest and are prohibited from taking for themselves personally opportunities that are discovered or may be available through the use of the corporation’s property information or position employees are prohibited from accepting meals entertainment travel gratuities merchandise or promotional material that could influence objectivity in making business decisions  fair dealing employees officers and directors should endeavour to deal fairly with the corporation’s partners researchers and suppliers and each other no one should take unfair advantage of anyone else through manipulation or misrepresentation of material facts protection and proper use of corporation assets all employees officers and directors should protect the corporation’s assets and ensure their efficient use confidentialityprivacy policy employees officers and directors should maintain the confidentiality of information entrusted to them by the corporation its partners researchers and its vendors and suppliers except when disclosure is authorized or legally mandated confidential information includes all non­public information further employees officers and directors should ensure compliance with the corporation’s “privacy policy” as such may be amended from time to time encouraging the reporting of any illegal or unethical behaviour many areas of the law such as securities and antitrust are very complicated the corporation encourages employees to talk to supervisors managers or other appropriate personnel when in doubt about the best course of action in a particular situation additionally employees should report violations of laws rules regulations or the code of business conduct and ethics to the chief executive officer of the corporation or the chairman of the corporate governance and nominating committee there will be no retaliation against anyone who presents this type of information in good faith disclosure of gifts to employees employees officers and directors will notify and receive permission from the board before accepting any gift trip etc of value over  the gift trip etc would not be prohibited if deemed to be a benefit to the employee and the corporation waiver of the code of business conduct and ethics there will be no waivers to the code of business conduct and ethics enforcement any violators of this code will be subject to disciplinary action the disciplinary actions will be determined by the board of directors or its designee the company intends such disciplinary action to reflect our belief that all employees officers and directors should be held accountable to the standards of conduct set forth herein accordingly such disciplinary action may include without limitation censure by the board demotion reassignment suspension or termination depending on the nature and the severity of the violation   transition therapeutics inc transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation about transition corporate overview management team board of directors contact us job opportunities business ethics no open positions âš  transition therapeutics inc transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation investor relations financial reports irs form  request information to request additional information please fill out the form below personal information first name last name email address organization address line  address line  city provincestate postalzip code country request âš  transition therapeutics inc transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation drug candidates elnd  agitationaggression elnd  down syndrome tt  diabetes and obesity tt  androgen deficiency product pipeline view transitions product pipeline latest news opko health to acquire transition therapeutics   irs form  âš  transition therapeutics inc transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation drug candidates elnd  agitationaggression elnd  down syndrome tt  diabetes and obesity tt  androgen deficiency product pipeline view transitions product pipeline latest news opko health to acquire transition therapeutics   irs form  âš  transition therapeutics inc transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation science  technologies product pipeline agitationagression in ad down syndrome diabetes and obesity âš  transition therapeutics inc transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation media center press release  press release archive webcast and presentation transition therapeutics inc investor day november   elnd on alzheimers disease  th clinical trials on alzheimers disease ctad presentation elnd for agitation and aggression in alzheimer’s disease harmonyad study phase  design and clinical outcomesauthors a porsteinsson et al elnd phase ii clinical study data in alzheimers disease safety and efficacy results of a phase  randomized placebocontrolled doseranging study of elnd scylloinositol in mild to moderate alzheimer’s diseasestephen salloway et aloriginal icad poster reformatted version imaging  cerebrospinal fluid biomarker results of a phase  doseranging study of elnd scylloinositol in mildmoderate addr anton porsteinson william b and sheila konar on behalf of elndad investigatorsicad presentation population pharmacokinetic analysis of plasma cerebrospinal fluid and brain elnd in patients with mild to moderate alzheimer’s diseaseearvin liang et aloriginal icad poster reformatted version a phase  randomized trial of elnd scylloinositol in mildmoderate alzheimer’s diseasesalloway et al neurology september   issuelink to neurology   transition therapeutics inc transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation clinical trials agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad randomized doubleblind placebocontrolled doseranging efficacy and safety study of oral elnd study design • approximately  participants aged  years with mild to moderate ad •    mg bid elnd vs placebo •  clinical sites across north america • protocol modified in december      discontinued  and  mg bid     mg and placebo to continue    last patient last visit in april  • status completed aug   link to press release primary outcome measures • safety and tolerability • cognitive and functional measures key findings • reduction in cognitive and functional decline in mild ad population • reduction in emergence of new neuropsychiatric symptoms including depression anxiety • evidence of target engagement csf and neuronal protection • acceptable safety and tolerability profile in humans • oral drug that crosses the bloodbrainbarrier • supports phase iii development in ad âš  transition therapeutics inc transition therapeutics inc usa nasdaqtthi quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinancetransition therapeutics inc usanasdaqtthiadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   transition therapeutics inc usa  public nasdaqtthi   watch this stock     close nasdaq realtime data  disclaimer currency in usd range       week      open      vol  mkt cap      pe      divyield      eps  shares m beta      inst own  news relevance date all news for transition therapeutics inc usa » subscribe advertisement key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  college st suite toronto on mg lcanada phone fax website links httpwwwtransitiontherapeuticsc external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry biopharmaceuticals more from factset » description transition therapeutics inc is a productfocused biopharmaceutical company the companys principal business activity is the researching and developing of therapeutic agents the company is developing therapeutics for central nervous system cns and metabolic disease indications the companys technologies are focused on the treatment of agitation and aggression in alzheimers disease and diabetes the companys subsidiary transition therapeutics ireland limited transition ireland is developing two drug candidates neuropsychiatric candidate elnd and androgen deficiency candidate tt the companys subsidiary waratah pharmaceuticals inc waratah is developing diabetes drug candidate tt the companys other two entities provide development services in support of the clinical and nonclinical activities of transition ireland and waratah more from reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service flashratings  principles facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings principles  flashratings mission is to provide you  the investor  with as much honest and professional research on your investments as possible  we believe its much better to get a multitude of credible opinions on an investment than to arbitrarily follow any single advisor  be it your banker a friend or a tv pundit  flashratings does not provide advice our job is to accurately and objectively report on analysts credible research and opinions the only advice flashratings will ever give you is to absorb as much fundamental research and different opinions as possible and make your own decisions  flashratings favors covering analysts with proven track records but will cover all analysts as long as their research is honest and professional sign up » transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation contact information corporate headquarter  college st suite  toronto on mg l t  contact us this web site is provided to you by transition therapeutics inc the “company” your use of this website is subject to the following terms and conditions as may be amended from time to time the “terms” your use of this website including by accessing browsing or subscribing to this website constitute your acceptance of the terms without modification if you do not agree please do not use this website the company reserves the right to change modify add or remove portions of this website and the terms at any time and you agree to be bound by such changes modifications additions or deletions  use of this website this website including all webpages content sounds software images site design text graphics the arrangement thereof and other data or information contained in this website the “content” is provided for informational purposes only you may view and print out web pages from this website for personal informational and noncommercial use but may not otherwise copy reproduce modify collect republish or catalogue any of the content without the company’s consent except as expressly permitted by the company you may not use this website or the content for commercial purposes  trademark and copyright notices the content is protected by copyright and other intellectual property laws and is owned or controlled by the company or the party credited as the provider of the content “transition therapeutics” and all other distinguishing words or logos relating to the company are trademarks of the company and may not be used without the prior written consent of the company all other trademarks service marks trade names andor other marks referred to on this website are the property of their respective owners  restrictions on use of this website except as expressly provided herein you may not use this website to engage in any unlawful activity or to infringe the rights of the company you further agree that you will and you will not allow your employees or agents to a modify republish upload post transmit sell or distribute in any way the content without the prior written permission of the company b translate reverse engineer decompile disassemble the content c remove any proprietary notices or labels on the content d violate plagiarize or infringe on the rights of any third party including copyright trademark privacy or publicity contract or other personal or proprietary rights e interfere with the operation of this website in any way or interfere with anyone’s use or enjoyment of this website or use this website to gain unauthorized access to other computer systems f transmit any unlawful harassing libellous defamatory abusive threatening or harmful material of any kind or nature or transmit any material that encourages conduct that could constitute a criminal offence give rise to civil liability or otherwise violate any applicable local provincial state national or international law or regulation g impersonate any person or entity on or through this website h post any content that may be considered threatening abusive vulgar obscene or otherwise objectionable i copy reproduce modify sell lease scrape content from or aggregate sublicense market or otherwise change or commercially exploit in any way this website other than as may be expressly permitted in writing by the company or as permitted pursuant to any fair use fair dealing or similar provisions of applicable laws any unauthorized use may subject you to civil liability and criminal prosecution under applicable laws you agree that any copy of this website or the content which you are permitted to take under the terms shall retain all copyright and other proprietary notices in the same form and manner as on the original  user submissions if the company provides any services which enable you to communicate with or otherwise share information with other persons on this website each a “submission” without limiting the generality of section  you will not submit publish display disseminate or otherwise communicate any libellous defamatory inaccurate abusive threatening offensive or illegal material in any submission transmission of such material or any material that violates any federal provincial or local law in canada or the laws of any other jurisdiction where this website is accessed from in any submission shall constitute a material breach of the terms entitling the company to terminate your rights to access this website the company does not and cannot review every submission and is not responsible for nor does it endorse any content of the submissions you remain solely responsible for the content of your submissions the company does not claim ownership of any submission and will not pay you for it however by providing the submissions to any area of this website including message boards forums contests and chat rooms you grant to the company its affiliates and sublicensees a royaltyfree perpetual irrevocable transferable worldwide nonexclusive right to copy use reproduce modify adapt publish translate create derivative works from distribute communicate to the public perform and display the submission in whole or in part andor to incorporate it in other works in any form media or technology now known or later developed for the full term of any rights that may exist in such submission you also warrant that the holder of any rights in such submission including any moral rights has completely and effectively waived all such rights and validly and irrevocably granted to you the right to grant the license stated above you also permit any user to access display view store and reproduce such submission for personal use subject to the terms the owner of such submission placed on this website retains any and all rights that may exist in such submission  disclaimers a accuracy of the content all content is provided on an as is and as available basis for informational purposes only and is subject to change without notice while this website is regularly updated the content may be inaccurate outofdate or otherwise incorrect the company assumes no liability or responsibility for any such errors omissions or inaccuracies and make no representations about the accuracy reliability completeness or timeliness of the content by using this website you acknowledge and agree that the company and its affiliates shareholders directors officers and employees are not and will not be subject to any liability based on any errors or omissions in the content whether or not any of such persons knew or should have known of any such errors or omissions in the content or were responsible for or participated in the inclusion or omission of content in this website b liability disclaimer the company provides this website and the content on an “as is” basis to the maximum as permitted by law the company disclaims all representations warranties and conditions express or implied with regard to the content as provided on this website including without limitation representations and warranties regarding currency fitness for a particular purpose merchantability merchantable quality noninfringement and timeliness of any product or service the company does not warrant that this website its servers the content and any communications from this website are free of viruses or other harmful components you expressly agree that your use of this website is at your sole risk c no solicitation this website and the information contained on this website including the content does not constitute an offer or a solicitation of an offer for the purchase or sale of any securities d no reliance on forwardlooking statements this website may include forwardlooking statements about the operations objectives and expected financial results of the company and others as part of the content statements that include the words “believes” “expects” “may” “will” “should” “seeks” “intends” “plans” “estimates” “anticipates” or the negative version of those words or other comparable terminology and similar statements of a future or forwardlooking nature identify forwardlooking statements by their nature such statements require the company to make assumptions and they are inherently subject to uncertainties that may be general or specific and arise from a variety of factors including but not limited to legislative or regulatory changes competition technological developments and global economic and financial conditions these factors many of which are beyond the company’s control affect the company’s operations objectives and expected financial results and could cause actual results performance or achievements to differ materially from any future results performance or achievements that may be expressed or implied by such forwardlooking statements having this in mind you are cautioned not to unduly rely on such forwardlooking statements they are not a substitute for the exercise of your own due diligence and judgment the outcomes anticipated in forwardlooking statements may not occur and the company does not undertake to update forwardlooking statements except as required by applicable securities law e no relationship your use of this website is not intended and shall not be deemed to create any legal relationship of any kind between you and the company nor to amend or vary any existing legal relationship  limitation of liability a you expressly understand and agree that the company its subsidiaries affiliates directors officers employees representatives licensors and licensees shall not be responsible or liable for any claims whatsoever including without limitation damages for loss of use data profits or other intangible losses related to or arising from directly or indirectly  your use or inability to use this website  your use of or reliance on the content contained in or through this website or  any other matter related to this website b you agree that the company and its subsidiaries affiliates directors officers employees representatives licensors and licensees shall not be liable for any indirect special incidental consequential or punitive damages whatsoever and howsoever caused arising out of or in connection with the use or misuse of this website or in reliance of the content available on this website including any business interruption loss of use lost data lost profits or any other pecuniary loss whether in action of contract civil liability negligence or other tortuous action even if the company has been informed of the possibility of such damages or such damages are reasonably foreseeable  indemnity you agree to indemnify defend and hold harmless the company and its subsidiaries affiliates directors officers employees representatives licensors and licensees from any claim or demand including reasonable attorneys fees made by any third party due to or arising out of your breach of the terms your misuse of this website or your violation of any law or the rights of a third party the company reserves the right at its own expense to assume the exclusive defense and control of any matter otherwise subject to indemnification by you and you shall cooperate as fully as reasonably required in the defense of any such claim  termination the company may in its sole discretion terminate the terms and terminate or suspend your access to all or part of this website or any portion thereof at any time without notice and for any reason including and without limitation breach of the terms or transmission of any illegal or offensive content or unsolicited advertising to this website sections      and  survive termination  hyperlinks to third party sites this website may contain hyperlinks to third party websites because the company has no control over such sites access to any other internet sites linked to this website is at your own risk and you understand that the company is not responsible for the availability accuracy or reliability of the contents of any linked site or any link contained in a linked site “third party content” the company provides these links to you only as a convenience and the inclusion of any link does not imply endorsement of any third party content by the company you further acknowledge and agree that the company shall not be responsible or liable directly or indirectly for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any third party content  your information the company collects uses and discloses your personal information in accordance with the privacy policy of this website the privacy policy is incorporated into the terms and is available at privacy policy by providing personal information to the company you consent to the use of personal information in accordance with the privacy policy  jurisdictional issues the company makes no representation that materials on this website are appropriate or available for use in all locations and is void where prohibited by law those who choose to access this website do so on their own initiative and are responsible for compliance with local laws if and to the extent local laws are applicable  general the company controls this website from toronto ontario canada these terms of use and your use of this website shall be governed by the laws of the province of ontario and the federal laws of canada applicable therein without reference to any choice of law or conflict of law principles and without reference to the uncitral convention on contracts for the international sale of goods any dispute arising under this agreement shall be resolved exclusively by the courts located in toronto in the province of ontario you agree not to bring any legal action against the company in any jurisdiction except the province of ontario and you shall submit and consent to such jurisdiction if any provision of this agreement shall be deemed unlawful by a court of law then the impugned provision shall be deemed severed and shall not affect the validity and enforceability of any remaining provisions  check back frequently please check back frequently to see any updates or changes to the terms  your continued use of this website following the posting of changes will mean you accept and agree to be bound by such changes   transition therapeutics inc flashratings  about us facebook autocomplete demo post a rating  month price target   trending sign up log in flashratings  all research for my stocks the most comprehensive equity research coverage available online never miss a single piece of research upgrade downgrade or target price change by any analyst firm on any stock equity research by professional analysts  especially their rationales more than their forecasts  contains far more interesting and important information about the actual fundamentals of the traded companies than can be gathered from conventional news reports our mission is to unlock access to valuable research on stocks for all retail investors professionals institutions take advantage of our costeffective subscriptions to have flashratingss comprehensive realtime feed delivered into your intranet and trading floor platforms institutional subscriptions websites become a content licensing partner and display flashratingss popular news feed on your website content licensing advertisers advertise with us and have flashratings readers with attractive demographics take advantage of your products advertising flashratings  contact us facebook autocomplete demo post a rating  month price target   trending sign up log in contact flashratings your emotional state excited confused worried upset panicked angry facebook autocomplete demo post a rating  month price target   home trending sign up log in analyst ranking   name measured ratings sucess rate avg return  mizuho      credit suisse      jefferies      cantor fitzgerald      bank of america merrill lynch      jmp securities      goldman sachs      raymond james      fbr capital markets      william blair     transition therapeutics inc profile use of this site is subject to and your continued use constitutes your express agreement to be bound by the  terms of use and  privacy statement any unauthorized use of this site is strictly prohibited xbrl voluntary filing program visit the csas xbrl website for information about xbrl and the voluntary program click here for information about xbrl software and viewing xbrl financial statements transition therapeutics inc mailing address transition therapeutics inc college streetsuite toronto onmg l head office address  college streetsuite toronto onmg l contact name nicole rusaw principal regulator ontario business email address nrusawtransitiontherapeuticscom short form prospectus issuer yes telephone number   reporting jurisdictions ceased reporting fax number   stock exchange tsx nasdaq date of formation jul   stock symbol jurisdiction where formed ontario auditor pricewaterhousecoopers llp industry classification consumer products  biotechnologypharmaceuticals general partner cusip number  transfer agent computershare investor services inc financial yearend jun  size of issuer assets  to  use of this site is subject to and your continued use constitutes your express agreement to be bound by the  terms of use and  privacy statement any unauthorized use of this site is strictly prohibited xbrl voluntary filing program visit the csas xbrl website for information about xbrl and the voluntary program click here for information about xbrl software and viewing xbrl financial statements microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft transition therapeutics inc home  contact us  disclaimer corporate overview management board of directors contact us job opportunities business ethics product pipeline agitationaggression in ad down syndrome diabetes and obesity inoutlicensing opportunity agitationaggression in ad down syndrome diabetes and obesity cognitionfunction in ad financial reports irs form  press release  press release archive webcast and presentation about transition corporate overview management team board of directors contact us job opportunities business ethics dr tony cruz chief executive officer dr cruz is one of the founders of transition therapeutics and has held the position of chief executive officer of transition therapeutics since its inception in july  dr cruz was a cofounder vicepresident and director at angiotech pharmaceuticals inc dr cruz has been a senior scientist at mount sinai hospital since  and was the ceo and president of the canadian arthritis network until  he has also served as a consultant for biotechnology companies and investment firms carl damiani president and chief operating officer mr damiani holds a broad leadership role in overseeing transition employees and activities in toronto san francisco and ireland as well as in the operations and advancement of the current development programs since joining transition in  mr damiani has held the roles of vicepresident of business development and director of business development nicole rusaw chief financial officer ms rusaw has been with the company since  and was appointed as chief financial officer in december  while at transition ms rusaw has been responsible for a broad range of activities with a focus on financial reporting and regulatory compliance as well as involvement in various equity financings and strategic acquisitions dr aleksandra pastrak vice president clinical development and medical officer dr pastrak has been with transition since  and served as vp research since  until she was appointed vp clinical development in  with her expertise in medicine and pharmacology she has made an invaluable contribution to the development of our clinical programs for various therapeutic products dr pastrak holds an md from the school of medicine at the university of belgrade and msc and phd degrees in clinical pharmacology from the university of toronto dr bruce connop vice president nonclinical  pharmaceutical development dr connop has been with transition since  and served as sr director nonclinical drug development until he was appointed vp nonclinical  pharmaceutical development in  with his expertise in pharmacology toxicology and manufacturing he is responsible for a broad range of activities and has made significant contributions to the advancement of pipeline products dr connop holds a phd from queenâs university and has had experience at other biotech and pharmaceutical companies  âš  transition therapeutics inc